Company: MLTX
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001140361-25-014923
Chunk: 34

Company: MoonLake Immunotherapeutics
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 34
---
 Silva |     |  $696,066 |     |  $662,920 |     | 5%         |
| Matthias Bodenstedt       |     |  $551,052 |     |  $524,811 |     | 5%         |
| Dr. Kristian Reich        |     |  $696,066 |     |  $662,920 |     | 5%         |

Annual Bonus Our Compensation Committee may approve annual bonuses for our named executive officers based on a review of Company performance and each named executive officer’s achievement of goals and objectives for the year. All executive officers are assigned annual bonus targets, expressed as a percent of base salary, based on each executive officer’s accountability, scope of responsibilities, and potential impact on performance, as well as peer group competitive data for similarly situated positions. The table below sets forth the target bonus for each NEO, which are the same as the target bonus opportunities in 2023:

| Name                      |     | 2024 Target Bonus  
 (% of Base Salary) |
| Dr. Jorge Santos da Silva |     | 55%                |
| Matthias Bodenstedt       |     | 50%                |
| Dr. Kristian Reich        |     | 55%                |

Each of our named executive officers is eligible to receive a bonus based on the achievement of reasonable financial and business objectives approved by, in the case of Dr. Santos da Silva, the Board (with input from the Compensation Committee) or, in the case of Mr. Bodenstedt and Dr. Reich, the Compensation Committee (with input from Dr. Santos da Silva). The performance objectives for the named executive officers for fiscal year 2024 were (i) building the Company and its profile with key stakeholders, (ii) delivering the SLK global programs in Hidradenitis Suppurativa and Psoriatic Arthritis, and (iii) securing financial stability. As determined by the Board or Compensation Committee, as applicable, each of Drs. Santos da Silva and Reich earned a payment of CHF 519,750 and Mr. Bodenstedt earned a payment of CHF 374,063 with respect to the achievement of their respective performance objectives for fiscal year 2024, reflecting a 150% achievement of their targets. Long-Term Incentive Compensation None of the named executive officers received any equity awards in 2024. In February 2025, each of the named executive officers received an equity award in the form